OT: Euthymics
Here's what I find most interesting, what was not mentioned:
(from 2004)" DOV Pharmaceutical Inc. licensed worldwide rights of its triple uptake inhibitor compounds for psychiatric disorders to Merck & Co. Inc. in a deal worth $455 million, if all milestones are met. The news caused DOV's stock (NASDAQ: DOVP) to climb $2.68 Friday, or 21.1 percent, to close at $15.40. Merck gains exclusive responsibility for development, manufacturing and commercialization of DOV. 21,947 for all psychiatric indications, and of DOV 216,303 to treat depression, anxiety and addiction. Dosing of the products has been completed in a Phase Ib and a Phase II trial, respectively."
Merck was not so impressed with the Phase II data for 21,947--they returned the rights to Dov, who then struggled for years to find anyone who did like the data, and essentially went out of business.
Euthymics paid a rock-bottom price:: "The acquisition price for DOV is for up to $2.0 million in cash, payable in two installments, representing a total of approximately $0.015 per share of DOV common stock."
On the other hand, you have very competent VCs, like Novartis Venture Fund, who see the Euthymics/Dov platform as worth a $24 million investment.
My view is that it is premature--indeed incorrect-- to assume that the optimal crossbalancing of triple amine reuptake inhibition effects has yet been identified and validated.
There are a number of clinical-stage approaches to Treatment-Resistant Depression out there, this is not necessarily the most appealing.
NeuroInvestment
